cms.bioaccessla.com

Blog

  • ANMAT trial authorization vs registro: Argentina’s 90-day study clock is not a selling license

    Sponsors still put “Argentina” on one regulatory Gantt with a single 90-day bar. That is the mistake. A first-in-human (FIH) or early feasibility study (EFS) for a medical device in Argentina runs as an ANMAT clinical-investigation file plus independent ethics and, where required, provincial oversight. Putting the same Class III implantable on the Argentine market later is a commercial registro under the live holder/HELENA checklist. Same agency name. Different petition, different importer, different success criterion.

    If the board slide says “ANMAT approved,” ask which ANMAT. Trial authorization is not a selling license. Do not put both on one Gantt labeled “Argentina.”

    Two files, one agency

    ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) is Argentina’s national authority for medicines, medical devices, and clinical research. It authorizes clinical investigations for devices used in-country. Ethics sits with an independent ethics committee under ISO 14155 and the Declaration of Helsinki, with provincial jurisdictions such as Buenos Aires providing additional oversight. Those are gates on the trial track, not a commercial license.

    For a U.S.-based medtech sponsor, the practical split looks like this:

    • Trial file: protocol, investigator brochure, informed consent in Spanish, independent ethics package, provincial filings where they apply, investigational labeling, ISO 14155 monitoring plan, and the import story for units that will only be used in the study. The Argentina clinical-trials hub already publishes a 90-business-day statutory review target; the clock pauses for RFIs, and FIH/EFS device studies often exceed that target. Treat 90 business days as a planning framework, not a guaranteed total start-up time.
    • Registro file: commercial sanitary registration for Classes I–IV under Disposición ANMAT N° 64/2025, including the simplified declaración jurada (DDJJ) route for CE-marked Class I/II through HELENA, with a local authorized representative / Technical Director ANMAT will treat as responsible for that certificate. The live ANMAT medical-device registration checklist is the commercial map. It is not a first-in-human permit.

    Argentina is a strict single-IoR example on the commercial track (AAR under Disp. 64/2025), already stated on the Ecuador single-IoR sibling post. That holder conversation belongs on market access. It does not clear investigational freight for a FIH.

    This site does not publish ANMAT as PAHO/WHO Level 4, and it does not invent an ICH-member claim. Headline ~30% lower versus typical US/EU programs is experience since 2010, not a formal study. None of those facts convert a trial authorization into a registro.

    What FDA reviewers will ask later

    If the Argentina FIH is meant to support a U.S. IDE or marketing file, design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States). That regulation expects GCP, independent ethics review, and a device comparable to the version you will put in front of FDA.

    ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean ANMAT investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, ethics correspondence, and provincial letters in one place from day one. Eligibility of foreign data under 812.28 is not a clearance prediction.

    File the federal, ethics, and provincial packages in parallel when the study design allows it. Sequential filing adds calendar time the statutory 90-business-day target never promised to absorb. Do not put a single “Argentina clock” on the Gantt and call it done.

    Import: investigational units are not the registro SKU

    A commercial ANMAT registration number does not clear investigational kits. Do not put a cousin SKU’s registro on the airway bill “because the PI knows customs.” Name the trial importer before ethics stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational, with lot or serial traceability that matches the accountability log at the site.

    After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy. The commercial HELENA / Class I–IV track — when you actually need it — is a separate workstream with its own importer and its own authorized representative.

    Holder vs distributor (commercial track only)

    When you later want Argentine market access, ANMAT will look for a local face on the sanitary registration: the authorized representative / Technical Director, renewals, variations, labeling, and vigilance. A distributor who only sells stock is not automatically that holder. Argentina’s single-IoR posture makes that point sharper, not softer. If the holder relationship breaks, the registro does not quietly follow the freight forwarder — you re-file.

    The market-access hub already describes ANMAT as risk-based Classes I–IV: lower-risk sworn declaration through HELENA, higher-risk several months on an experience-based clock that is not a statutory cap. Do not collapse that commercial clock into the trial 90-business-day target. Running them as one “Argentina regulatory” workstream is how teams discover, mid-enrollment, that nobody can import the commercial launch SKU.

    One-page gate before first patient in Argentina

    Write these lines with owners and document IDs before you book site initiation:

    1. Authority map. ANMAT investigation plus independent ethics (and provincial oversight where required) for the study. Commercial registro under Disp. 64/2025 / HELENA only if a parallel market-access file is truly in scope this year.
    2. Ethics + investigation sequence. Same protocol version and the same Spanish informed-consent text across federal, ethics, and provincial packages. Plan for RFI pauses on the 90-business-day statutory target.
    3. Investigational importer. Legal name and the document that ties the shipment to the investigation authorization — not a commercial registro number and not a HELENA DDJJ reference.
    4. Device list. Every unit that will sit in the site accountability log, including accessories.
    5. ISO 14155 file owner. Who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
    6. Commercial holder (optional, separate). If launch is real, name the Argentine authorized representative / Technical Director and keep that file off the FIH critical path until first patient is locked.

    Where teams burn weeks

    Three patterns show up repeatedly on Argentina device files:

    • One 90-day bar for both desks. Treating the statutory trial review target as if it also covered Classes I–IV commercial registration. The checklist is a second file. Higher-risk commercial work often runs several months on experience, not on the trial clock.
    • Registro number on investigational freight. Using a commercial ANMAT certificate for a predicate or related model to move FIH units. The investigational article is not that registered product.
    • One Spanish translation for both desks. The informed-consent and brochure language for ethics and the investigation is not the commercial IFU ANMAT will later lock on a registro. Mixing them creates labeling debt on both tracks.

    Fix the patterns on paper before translators start. Re-translation after first patient is a protocol amendment problem, not a word-processing problem. The CRO in Argentina category page and the registration checklist already keep trial and registro apart — keep your Gantt the same way.

    Practical next step

    This week, split the Argentina slide into two columns: ANMAT investigation and ANMAT registro. If the same person owns both without two dossiers, two importers, and two success criteria, you do not have an Argentina plan — you have a hope. bioaccess® runs FIH/EFS execution across Latin America, including Argentina from Miami, and holds LATAM registration/IOR work as a separate market-access track; treat Argentina the same way inside your own team. Start from the clinical-trials hub for the investigation column and the ANMAT checklist for the registro column — and do not collapse them because both say ANMAT.

  • El Salvador CNEIS/SRS trial authorization vs DNM registro: keep the FIH file off the commercial holder track

    Sponsors still put “El Salvador” on one regulatory Gantt with a single 30–60 day band. That is the mistake. A first-in-human (FIH) or early feasibility study (EFS) for a medical device in El Salvador runs as a CNEIS ethics vote plus an SRS clinical-investigation authorization. Putting the same Class III implantable on the Salvadoran market later is a DNM/SRS registro sanitario. Same clock language. Different petition, different importer, different success criterion.

    If the board slide says “El Salvador approved in 30–60 days,” ask which file. Trial authorization is not a commercial registro. Confusing them delays first patient and later stalls commercial import.

    Two files, one country

    The Superintendencia de Regulación Sanitaria (SRS), established in August 2024 under the Ley de la Superintendencia de Regulación Sanitaria (7 August 2024), replaced the Dirección Nacional de Medicamentos (DNM) as El Salvador’s national sanitary authority. Ethics for clinical research sits with the Comité Nacional de Ética de la Investigación en Salud (CNEIS). Parallel SRS and CNEIS review is already published on the El Salvador clinical-trials hub as the reason that country page shows a 30–60 day study-startup band.

    For a U.S.-based medtech sponsor, the practical split looks like this:

    • Trial file: Spanish protocol package, investigator brochure, informed consent, CNEIS ethics package, SRS investigation authorization, investigational labeling, ISO 14155 monitoring plan, and the import story for units that will only be used in the study. The live step-by-step FIH guide already names the SRS-CNEIS-ES digital platform and the user manual issued 17 November 2025. Use that manual. Do not invent article numbers from CNEIS reforms you have not opened.
    • Registro file: commercial sanitary registration through DNM/SRS for manufacture, import, storage, distribution, and promotion of a commercial device, with a Salvadoran party the authority will treat as responsible for that certificate — not a PI’s clinic stamp and not a named hospital that happens to have run FIH.

    Hospital El Salvador appears on the public landscape as infrastructure. It is not a hospital bioaccess® operates, and it is not the commercial titular on a registro. Public San Salvador sites are sites. They are not the CRO and they are not the holder.

    The same 30–60 day language also appears on the market-access hub for El Salvador commercial registration (experience-based). That is the punchline: identical band, different petition. the two clocks is separate from one Gantt bar labeled “El Salvador.”

    What FDA reviewers will ask later

    If the El Salvador FIH is meant to support a U.S. IDE or marketing file, design the investigation so the evidence room can satisfy 21 CFR § 812.28 (acceptance of data from clinical investigations conducted outside the United States). That regulation expects GCP, independent ethics review, and a device comparable to the version you will put in front of FDA.

    ISO 14155 is the device GCP bridge FDA has publicly recognized for foreign investigations. A clean SRS investigation letter does not replace an inspectable trial master file. Keep device accountability, deviation logs, monitoring reports, and the CNEIS correspondence in one place from day one. Eligibility of foreign data under 812.28 is not a clearance prediction.

    El Salvador is a lead FIH jurisdiction for bioaccess®, with Miami headquarters and a dollarized economy already published on the country hub. None of that converts a trial authorization into a selling license. Do not put a single “El Salvador clock” on the Gantt and call it done.

    Import: investigational units are not the registro SKU

    A commercial DNM/SRS registration number does not clear investigational kits. Do not put a cousin SKU’s registro on the airway bill “because the PI knows customs.” Name the trial importer before CNEIS stamps the protocol. Map every investigational model, accessory, and spare to the investigation-authorized list. Outer labels must read as investigational, with lot or serial traceability that matches the accountability log at the site.

    After last patient, close investigational inventory under the trial rules. Leaving units “for the hospital” without a new sanitary path is a new regulatory event, not a courtesy. The commercial registro track — when you actually need it — is a separate workstream with its own importer and its own holder.

    Holder vs distributor (commercial track only)

    When you later want Salvadoran market access, SRS will look for a local face on the sanitary registration: renewals, variations, labeling, and vigilance. A distributor who only sells stock is not automatically that holder. If the holder relationship breaks, the registro does not quietly follow the freight forwarder — you re-file.

    That commercial conversation belongs on a separate workstream from the investigation calendar. Running them as one “El Salvador regulatory” workstream is how teams discover, mid-enrollment, that nobody can import the commercial launch SKU. The market-access hub already states that commercial registration is a second file. Keep it that way inside your own team.

    One-page gate before first patient in El Salvador

    Write these lines with owners and document IDs before you book site initiation:

    1. Authority map. SRS investigation plus CNEIS ethics for the study. DNM/SRS registro only if a parallel commercial file is truly in scope this year.
    2. Ethics + investigation sequence. Same protocol version and the same Spanish informed-consent text in both packages. Submit through the SRS-CNEIS-ES platform already named on the live FIH guide; use the 17 November 2025 user manual as the operational reference.
    3. Investigational importer. Legal name and the document that ties the shipment to the investigation authorization — not a commercial registro number.
    4. Device list. Every unit that will sit in the site accountability log, including accessories.
    5. ISO 14155 file owner. Who can produce monitoring, accountability, and ethics letters within 48 hours if FDA or a notified body asks.
    6. Commercial holder (optional, separate). If launch is real, name the Salvadoran titular and keep that file off the FIH critical path until first patient is locked.

    Where teams burn weeks

    Three patterns show up repeatedly on El Salvador device files:

    • One 30–60 day bar for both desks. Treating the published study-startup band and the experience-based commercial registration band as the same petition. They share clock language. They do not share a dossier.
    • Registro number on investigational freight. Using a commercial DNM/SRS certificate for a predicate or related model to move FIH units. The investigational article is not that registered product.
    • One Spanish translation for both desks. The informed-consent and brochure language for CNEIS and the investigation is not the commercial IFU SRS will later lock on a registro. Mixing them creates labeling debt on both tracks.

    Fix the patterns on paper before translators start. Re-translation after first patient is a protocol amendment problem, not a word-processing problem. Sibling posts on the same split for other LATAM markets — including the CRO in El Salvador category page — already make the same point: trial and registro are not one Gantt.

    Practical next step

    This week, split the El Salvador slide into two columns: CNEIS/SRS investigation and DNM/SRS registro. If the same person owns both without two dossiers, two importers, and two success criteria, you do not have an El Salvador plan — you have a hope. bioaccess® runs FIH/EFS execution across Latin America, including El Salvador as a lead FIH jurisdiction from Miami, and holds LATAM registration/IOR work as a separate market-access track; treat El Salvador the same way inside your own team. Start from the clinical-trials hub for the investigation column and the market-access hub for the registro column — and do not collapse them because both say 30–60 days.

  • PMA Clinical Trial Requirements: How to Build the Clinical Evidence Package FDA Expects

    PMA Clinical Trial Requirements: How to Build the Clinical Evidence Package FDA Expects

    A PMA clinical trial is one of the most demanding regulatory milestones a medical device company will face. Unlike the 510(k) pathway, which relies on substantial equivalence to a predicate, Premarket Approval requires you to generate original clinical evidence demonstrating that your device is safe and effective for its intended use. The FDA will not approve a Class III device on bench data and animal studies alone. You need a clinical evidence package, and it needs to be built correctly from the start.

    This article covers what the FDA expects, how to structure that package, where most sponsors go wrong, and how your trial execution strategy affects the quality and timing of the data you ultimately submit.

    What Makes a PMA Different From Other Approval Pathways

    The PMA pathway applies to Class III devices: those that support or sustain human life, present a potential unreasonable risk of illness or injury, or lack a substantially equivalent predicate. Implantable cardiac devices, neurostimulators, and certain diagnostic systems are common examples.

    Because no predicate exists, the FDA requires sponsors to prove safety and effectiveness through valid scientific evidence. That standard is defined in 21 CFR Part 860 and typically means well-controlled clinical investigations producing statistically valid results.

    The 510(k) pathway can sometimes be cleared with retrospective data or literature reviews. The PMA pathway almost never can. You are building a prospective clinical record from scratch.

    The Core Components of a PMA Clinical Evidence Package

    The FDA expects the clinical section of a PMA submission to contain several interconnected elements. Missing or underpowered components are the most common trigger for Additional Information (AI) requests and major deficiencies.

    Investigational Device Exemption (IDE) Approval

    Before enrolling a single patient in a significant-risk device study, you need an approved IDE under 21 CFR Part 812. The IDE authorizes use of your device in human subjects during the investigation phase. For significant-risk devices, it is not optional.

    Your IDE application must include the investigational plan (protocol), a risk analysis, device description, informed consent procedures, IRB approvals, and a monitoring plan. The FDA has 30 days to respond. If they do not disapprove it within that window, you may proceed.

    The IDE is the foundation of your clinical evidence package. A weak protocol produces weak data. What you write at this stage directly determines whether the evidence you collect will hold up in the PMA submission.

    Clinical Protocol and Study Design

    The protocol is where most sponsors either set themselves up for success or create problems they will spend years correcting. The FDA expects a study design that:

    • Defines a primary endpoint that maps directly to the device's intended use
    • Specifies a statistically justified sample size with power calculations
    • Identifies a control arm or objective performance criteria (OPC) where applicable
    • Describes follow-up duration sufficient to capture the safety and effectiveness signals relevant to the indication
    • Pre-specifies analysis populations (intent-to-treat, per-protocol) and statistical methods

    Adaptive designs are increasingly accepted, but they require pre-specification of adaptation rules and FDA agreement before the trial begins. Do not adapt your protocol mid-study without prior FDA concurrence.

    Pre-Submission (Q-Sub) Meetings

    Before finalizing your protocol, request a Pre-Submission (Pre-Sub) meeting with the FDA under the Q-Submission program. This is one of the highest-leverage steps available to any PMA sponsor. A Pre-Sub gives you written FDA feedback on your proposed study design, endpoints, and statistical analysis plan before you commit to executing the trial.

    Sponsors who skip the Pre-Sub and design protocols in isolation frequently discover at the PMA review stage that the FDA had different expectations about endpoint definitions, follow-up duration, or the adequacy of the control. That discovery, made after data collection is complete, is expensive and sometimes fatal to the program.

    Use the Pre-Sub to confirm your primary endpoint, discuss the acceptability of your control strategy, and align on what "valid scientific evidence" means for your specific device and indication.

    Statistical Analysis Plan (SAP)

    The SAP must be finalized and locked before unblinding or completing enrollment. It specifies every analysis the FDA will review: primary and secondary endpoint analyses, subgroup analyses, handling of missing data, multiplicity adjustments, and interim analysis rules if applicable.

    A SAP written after the fact, or one that does not match the protocol, is a major deficiency. The FDA's reviewers are statisticians. They will compare your SAP to your protocol and to your actual analysis. Discrepancies get flagged.

    Clinical Study Report (CSR)

    The CSR is the formal document presenting all clinical findings from your investigation. It follows ICH E3 structure and must include:

    • Full protocol and amendments
    • Patient disposition and demographics
    • Primary and secondary endpoint results with confidence intervals
    • Adverse event and serious adverse event summaries
    • Subgroup analyses
    • Individual patient data listings

    The CSR is not a summary. It is a complete, auditable record of what happened in the trial. The FDA reviewer will read it alongside your raw data. Inconsistencies between the narrative and the data tables are a recurring source of deficiencies.

    Device History and Bench Data

    The clinical section does not stand alone. The FDA reviews it alongside your device description, bench testing, biocompatibility data (ISO 10993), sterilization validation, and software documentation where applicable. The clinical evidence package must be internally consistent with the device you tested. If your final design changed after IDE approval, document those changes and assess whether they affect the clinical data's applicability.

    Where Sponsors Build Weak Evidence Packages

    Several patterns consistently produce deficient PMA submissions.

    Underpowered studies. Sample size calculations that assume unrealistically high effect sizes or low event rates result in studies that cannot demonstrate effectiveness even when the device performs well. The FDA will not accept a study that was never capable of answering the question it was designed to answer.

    Endpoint drift. Changing the primary endpoint after data collection begins, even informally, is a serious problem. If your final CSR analyzes a different primary endpoint than the one in your IDE-approved protocol, the FDA will treat the original endpoint as primary and the new one as exploratory. Plan your endpoints carefully and hold to them.

    Inadequate follow-up. For implantable or long-term-use devices, the FDA often expects data at 12, 24, or 36 months. Sponsors who design studies with six-month follow-up to save time frequently receive AI requests requiring additional data collection, extending the overall timeline by more than the time they tried to save.

    Site qualification gaps. Sites that are not properly qualified, trained, or monitored produce data with integrity questions. The FDA can and does inspect clinical sites during PMA review. Data from sites with significant protocol deviations or monitoring deficiencies may be excluded from the analysis.

    Missing or incomplete informed consent documentation. Every enrolled patient must have a properly documented informed consent process. Missing consent forms, or forms that do not reflect the approved protocol version, are a recurring finding in FDA inspections.

    How Trial Location Affects Your Evidence Package

    Where you run your PMA clinical trial has a direct effect on how quickly you can generate data and what it costs to generate it. These are not trivial considerations when your runway is finite and your board is watching the milestone calendar.

    US-based trials for significant-risk devices face IRB review timelines of three to six months per site, site activation timelines that often stretch beyond a year for complex devices, and per-patient costs that can run well above $30,000 depending on the indication and site infrastructure.

    Latin American markets operate differently. In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are consistently observed in 30 to 90 days. That reflects actual observed performance across those markets, not a contractual guarantee from the health authorities. Patient populations in these countries are often treatment-naive for novel devices, which can improve enrollment rates and reduce the confounding effect of prior interventions on your primary endpoint.

    The critical question for PMA purposes is whether data collected outside the US will be accepted by the FDA. The answer is yes, when the data is collected under an IDE and structured in accordance with 21 CFR 812.28, which governs the acceptance of foreign clinical study data. The study must be conducted under conditions comparable to US standards, using ICH-GCP-compliant protocols and ISO 14155 trial architecture. When those conditions are met, foreign clinical data supports both IDE and PMA submissions.

    This is not a workaround. It is an established FDA framework that sponsors have used to accelerate timelines without compromising the quality of the evidence package.

    Building the Evidence Package With a Single Accountable Team

    The most common operational failure in PMA clinical programs is fragmentation. Sponsors use one vendor for regulatory strategy, a second for protocol development, a third for site management, and a fourth for data management. When the FDA asks a question about the relationship between a protocol amendment and a data collection change, no single person can answer it. The evidence package reflects the seams between vendors.

    A structured approach that covers all workstreams under one accountable team produces a more coherent evidence package and a faster path through FDA review. Every component, from the Pre-Sub meeting through the final CSR, needs to be built by people who understand how each piece connects to the next.

    bioaccess® operates the FIH-12 program on exactly this model: nine workstreams managed by a single team, from FDA Pre-Sub and IDE/IND pathway alignment through protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package within a 12-month timeline. Trial execution runs across 19 Latin American and Caribbean markets through a network of 50-plus pre-qualified sites, with the final deliverable structured for the sponsor's next FDA regulatory step.

    For PMA programs, that means the CSR and organized data room arrive ready for submission, not requiring reconstruction by a regulatory affairs team that was not present during the trial.

    The Pre-PMA Submission Checklist

    Before submitting your PMA, the clinical section should contain the following:

    • Approved IDE and all amendments
    • Final protocol with all versions documented
    • Locked statistical analysis plan
    • IRB approvals for all sites
    • Informed consent forms for all enrolled patients
    • Clinical study report following ICH E3 structure
    • Adverse event narratives for all serious adverse events
    • Individual patient data listings
    • Site monitoring reports and audit trails
    • Investigator qualifications and CVs
    • Device accountability records

    If any of these elements is missing or incomplete at submission, expect an AI request. AI requests add months to your review timeline. Getting the evidence package right before submission is faster than correcting it afterward.

    What the FDA Reviews in the Clinical Section

    The FDA's review of the clinical section focuses on several core questions:

    1. Was the study designed to answer the right question for the intended use?
    2. Was it conducted in accordance with the approved protocol and applicable regulations?
    3. Does the primary endpoint analysis demonstrate a reasonable assurance of safety and effectiveness?
    4. Are the adverse event data complete and accurately reported?
    5. Do the benefits outweigh the risks for the intended patient population?

    Reviewers are not looking for perfection. They are looking for scientific rigor, regulatory compliance, and honest reporting. A well-designed study showing modest benefit with a clear safety profile is more likely to succeed than an ambitious study with data integrity problems.

    FAQs: PMA Clinical Trial Requirements

    What is a PMA clinical trial and when is it required?
    A PMA clinical trial is a clinical investigation conducted to generate the safety and effectiveness data required for FDA approval of a Class III medical device. It is required when a device cannot be cleared through the 510(k) pathway because no substantially equivalent predicate exists, or when the device presents a high risk to patients.

    Do I need an IDE before starting a PMA clinical trial?
    Yes. For significant-risk devices, an approved Investigational Device Exemption (IDE) under 21 CFR Part 812 is required before enrolling patients. The IDE application includes your protocol, risk analysis, device description, and IRB approvals. The FDA has 30 days to respond before you may proceed.

    Can I use clinical data collected outside the United States in a PMA submission?
    Yes. Foreign clinical data is accepted in PMA submissions when collected under an IDE and structured in accordance with 21 CFR 812.28. The study must be conducted under ICH-GCP-compliant conditions and meet the applicable FDA standards for the evidence type.

    What is a Pre-Submission meeting and why does it matter for PMA programs?
    A Pre-Submission (Pre-Sub or Q-Sub) meeting is a formal FDA feedback mechanism that allows sponsors to get written agency input on study design, endpoints, and statistical approaches before committing to a trial. For PMA programs, it is one of the most important steps you can take to reduce the risk of a major deficiency at the review stage.

    How long does a PMA clinical trial typically take?
    Timeline depends on the indication, study design, enrollment rate, and follow-up requirements. US-based trials for significant-risk devices commonly take 18 to 36 months from IDE approval to CSR completion. Trials executed in Latin American markets with faster regulatory approval timelines can compress the pre-enrollment phase significantly, though follow-up duration is determined by the protocol, not the geography.

    What is the most common reason for a PMA clinical deficiency?
    Underpowered study designs, endpoint drift, inadequate follow-up, and site data integrity issues are the most frequent sources of major deficiencies. Endpoint drift is the most preventable, and it is eliminated by finalizing your endpoints during the Pre-Sub process and locking your SAP before data collection begins.

    How should the clinical study report be structured for a PMA submission?
    The CSR should follow ICH E3 structure and include the full protocol and amendments, patient disposition, primary and secondary endpoint results with confidence intervals, adverse event summaries, subgroup analyses, and individual patient data listings. It must be internally consistent with the data tables and the approved protocol. Inconsistencies between the narrative and the data are a common source of AI requests.

    Build the Evidence Package Before You Need It

    The clinical evidence package for a PMA submission is not something you assemble at the end of a trial. It is built incrementally, starting with the Pre-Sub meeting and ending with a locked CSR and organized data room. Every decision made during protocol development, site selection, and data management either strengthens or weakens the package you will eventually hand to the FDA.

    Sponsors who treat the evidence package as a documentation exercise discover its importance during review. Sponsors who treat it as the product of the trial build programs that move through FDA review with fewer deficiencies and shorter timelines.

    If you are planning a PMA clinical trial and want to understand how trial execution in Latin America fits into your FDA evidence strategy, bioaccess® works with MedTech sponsors at exactly this stage of program planning.

    WordPress category: Navigating Regulatory Landscapes in Latin America

  • How to Scale Medical Device Registration Across 19 Latin American Markets

    Registering a device in one Latin American market is a project. Registering in 19 is an operating system. The system breaks when a US or EU manufacturer treats each country as a local-distributor errand: a different titular in Mexico, a different detentor in Brazil, a different titular in Colombia, a droguería that also sells the catalog in Peru. Six months later the certificates exist and the manufacturer does not control them.

    I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator brief for teams that already have FDA clearance, approval, or a CE mark, and need sanitary registration across Latin America without converting the license into the distributor’s hostage. bioaccess® LATAM market access uses two-part pricing: a one-time registration fee per country by device class, then a lower annual holder fee from year 2 (published for Mexico, Colombia, Brazil, Peru and Argentina on the rate card). Coverage is 19 markets. Six core desks sit on that page: ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID.

    The distributor-as-holder trap

    Every Latin American regulator ties a device registration to an in-country legal entity. That entity is the titular, detentor, representante autorizado, or registration holder. On it sit tecnovigilancia, answers to the authority, variations, and — in several markets — importation. The distributor is a different function: sells, invoices, services. When the two functions sit in the same company, you do not have a channel. You have a partner who also owns the regulatory asset. Changing the partner means cesión de derechos, a new registro, or both.

    That is how the instruments are written:

    • Mexico (COFEPRIS). The named titular on the Registro Sanitario is the sanitary face of the product. A Mexico Registration Holder can name several distributors and importers on one certificate — which is why an independent holder is useful and a distributor-titular is expensive to unwind. As of 20 August 2026 you can check the named titular on the public Visor de Registros Sanitarios de Dispositivos Médicos (COFEPRIS Comunicado 21/2026). If your Mexican distributor is the name the visor shows, channel termination does not move the certificate.
    • Brazil (ANVISA). RDC No. 751 of 15 September 2022 names a single detentor de registro. The foreign manufacturer cannot be that detentor. RDC 270/2019 lets the detentor authorize several importers without re-registering the device. A Brazil Registration Holder that is not the exclusive importer is the correct design.
    • Colombia (INVIMA). Decreto 4725 of 2005 is the sanitary-registration statute. INVIMA contemplates one titular with several importers. The manufacturer does not have to hand titularidad to the first commercializer.
    • Peru (DIGEMID). The titular must be an authorized pharmaceutical establishment, typically a droguería, under Ley N° 29459 and Decreto Supremo N° 016-2011-SA. Decreto Supremo N° 001-2024-SA lets an independent Peru Registration Holder sit apart from the distributor; other droguerías can obtain their own CRS to import a product already registered by another titular. The live Peru DIGEMID page already states that model.
    • Argentina (ANMAT). One authorized representative per registro; that representative is titular and importer. Disposición 2318/2002 was replaced by Disposición 64/2025. Changing AAR usually means registering again. The same single-representative logic applies in Ecuador (Resolución ARCSA-DE-026-2016-YMIH, as amended by ARCSA-DE-2023-033-AKRG), El Salvador (SRS), Panama (Ley 90 of 2017 and Decreto Ejecutivo No. 490 of 4 October 2019), and DIGEMAPS in the Dominican Republic.

    bioaccess® holds registrations through its own local entities for the manufacturer’s benefit, with defined transfer provisions in the agreement. Importer rules: LATAM importer-of-record guide.

    Classification logic diverges — ANVISA, COFEPRIS, INVIMA, DIGEMID

    US regulatory affairs teams still paste a single “Class II” onto a 19-country tracker. That is how dossiers bounce. Four large desks do not share a classification statute, a class count, or a review regime. A device that is Class II at FDA can be Class III at COFEPRIS because it stays in the body more than 30 days, Class III at ANVISA because it is a long-term implant, Class IIb at INVIMA, and Class III or IV at DIGEMID. Classify in each rule set. Do not infer.

    Brazil — ANVISA, four classes, two regimes. RDC 751/2022 Article 5: Class I low, II medium, III high, IV maximum risk, using 22 rules in Annex I. Articles 6–7: Classes I and II go to notificação; Classes III and IV go to registro, with statutory maximums up to about 250 days (equipment), 320 days (materials), and 365 days (IVDs). Implantable and long-term surgically invasive devices default to Class III unless a specific rule says otherwise. A US 510(k) orthopedic implant does not automatically enter Brazilian notificação.

    Mexico — COFEPRIS, three classes, duration-and-novelty logic. Reglamento de Insumos para la Salud, Article 83: Class I — known in medical practice, generally not introduced into the body; Class II — known in practice, generally introduced and remaining fewer than 30 days; Class III — new or recently accepted, or introduced and remaining more than 30 days. That last “or” is the trap for biomaterials and implants. The equivalence route (vía abreviada) is for devices already approved and marketed by the same manufacturer in a reference country (US FDA, Health Canada, or Japan). A CE mark alone does not qualify. Standard response times on the market-access page: about 30 / 35 / 60 working days by class I / II / III.

    Colombia — INVIMA, four classes with a IIa/IIb split. Decreto 4725 of 2005, Article 5: Class I low risk, IIa moderate (special controls in manufacture), IIb high (special controls in design and manufacture), III very high risk. Class I and IIa receive registro sanitario automático. Class IIb and III undergo full prior review on the order of ~90 business days. A US “Class II” memo has to land on IIa or IIb; that choice is automatic issuance versus a 90-business-day file.

    Peru — DIGEMID, four classes, separate classification regulation. Decreto Supremo N° 003-2020-SA sets classification rules and essential principles of safety and performance: Class I low, II moderate, III high, IV critical. Registration, control, and vigilance remain Decreto Supremo N° 016-2011-SA (as amended, including Decreto Supremo N° 011-2022-SA), under Ley N° 29459. DIGEMID’s device page points at Articles 124–127 for requirements by risk level. Imports run through a licensed droguería. Do not treat a Colombian Class IIa decision as a Peruvian Class II decision.

    Chile (ISP), Argentina (ANMAT, Classes I–IV), Panama (GHTF/IMDRF under Ley 90 / Decreto 490), and the rest of the 19-market list add more logic, not less. The operating move is a classification matrix: one row per SKU, one column per authority, intended-purpose sentence, rule, class, regime. If those cells disagree with the US product-code memo, the US memo loses.

    Consolidate independent in-country authorized representation

    The alternative to 19 distributor-holders is one doctrine of local authorized representation (LAR) / registration holder, executed through dedicated in-country entities that do not sell the device. Lock these five roles per country before anyone signs a distribution LOI:

    1. Who is the titular / detentor / AAR / PRH. A manufacturer branch, an independent professional holder, or the distributor. Pick one on purpose. Independent holder is the default that keeps the certificate movable.
    2. Who may import. One IOR (Argentina, Panama, many single-representative markets) versus several importers on one registro (Mexico, Colombia, Brazil under RDC 270/2019, Peru via additional CRS). Write the commercial contract to the sanitary fact, not the other way around.
    3. Who files tecnovigilancia and field actions. In Mexico, Brazil, and Colombia the local holder must run a named system after the certificate is granted (Ley General de Salud art. 262 Bis and NOM-240-SSA1-2012 §6.7.12; RDC 67/2009 art. 3; Resolución 4816/2008). If that system fails, the registro can be suspended or cancelled.
    4. Who owns variations. Model adds, software bumps, sterile-barrier changes. Quiet EU updates do not auto-propagate into COFEPRIS, ANVISA, INVIMA, or DIGEMID.
    5. Who holds the translation memory. Certified Spanish or Portuguese of IFU, labels, and technical file — sworn where Brazil and Argentina require it. If a distributor commissions the translation, they hold the glossary you will need at renewal.

    bioaccess®’s published structure is that independent holder, through our own local entities, across the 19-market footprint. We register FDA-cleared (510(k)) or approved (PMA), or CE-marked, devices. We do not obtain FDA clearance or CE marking on your behalf. As of the July 2026 market-access card: 25+ device registrations completed; 25+ active registrations held through bioaccess®’s own in-country entities; 15+ years on COFEPRIS, INVIMA, ANVISA, and ANMAT. Figures are self-reported. If the commercial plan is one country and a local holder with its own entity is enough, that product is valid. If the plan is several certificates under the same transfer doctrine, stop hiring a new local agent per capital.

    Flat-subscription maintenance versus one-off consulting fees

    One-off RA consulting sells a dossier. The certificate then sits with whoever filed it, and every variation, renewal, and adverse-event clock is a new statement of work. That is how a 19-country plan becomes 19 uncoordinated invoices.

    bioaccess® pricing is two-part: a one-time registration fee per country (by device class), then a lower annual holder fee from year 2. One-time registration fee per country by class (Class I/II, IIa/IIb, III/IV): Mexico $5,000 / $8,000 / $13,250; Colombia $4,000 / $6,250 / $9,000; Brazil $6,750 / $11,500 / $22,250; Peru $4,250 / $6,500 / $10,500; Argentina $4,500 / $6,500 / $12,000. Annual holder fee from year 2: Mexico $4,500; Colombia $3,900 (our own Colombian entity holds the registration); Brazil $6,000 (Class I/II) or $7,500 (Class III/IV); Peru $4,200; Argentina $4,200. USD, excluding VAT and local taxes. Chile is quoted case by case. Prices are valid for agreements signed by 31 March 2027; this is information only, not an offer. Full table on the rate card.

    Outside the flat fee: Brazil BGMP manufacturing-site audit (about USD 13,500/site), INMETRO, ANATEL, and telecom/EMC + RF homologation for wireless devices — billed at vendor cost + 20% G&A. Those telecom filings run through IFT, ANATEL, ENACOM, SUBTEL, or CRC, not the health authority. Importer-of-record logistics: quoted separately per shipment (no charge if there is no import).

    Typical competitor unbundling already published on the market-access page: government fees USD 1,500–5,000 per country; translations USD 4,000–15,000; registered agent USD 3,000–5,000 per year; liaison USD 500–2,000 per month. Global RA consultancies typically quote USD 15,000–30,000 per country for registration alone. Pure Global’s published Mexico/Brazil sticker is USD 2,000–3,000 for dossier + holder (PR Newswire, 5 February 2026) — a different SKU, with no published tecnovigilancia price.

    Agency queries pause any statutory period. Typical time-to-registration once the dossier is in: 90 days for low-risk devices and 120 days for Class II/III, varying by country and class.

    Build the system, then pick the first three countries

    1. Write the intended-purpose sentence in Spanish and Portuguese. If the team cannot agree on one sentence, stop. Classification will not survive three agencies.
    2. Fill the classification matrix for ANVISA, COFEPRIS, INVIMA, and DIGEMID — then the remaining markets on the launch list. Record the rule, the class, and the regime.
    3. Name the independent holder per country before any distribution LOI. Confirm, in Mexico, that the visor will show that name once the registro is vigente.
    4. Separate the first-in-human file if you still need patients. Trial authorization and commercial registro are different desks. We still run first-in-human work in Colombia when the device, sites, and file fit — that is not a reason to hand INVIMA titularidad to a distributor.
    5. Put maintenance on a flat annual subscription so variations, renewals, and tecnovigilancia are not a new consulting event.

    Learn about bioaccess® market access at bioaccessla.com/market-access. Country pages for ANVISA, COFEPRIS, INVIMA, ANMAT, ISP, DIGEMID, and MINSA sit under that hub. Importer rules: LATAM importer of record.

  • Why US Medtech Startups Are Choosing Panama for Class III First-in-Human Trials

    US orthopedic and biomaterial startups still treat first-in-human as a domestic IDE problem. The calendar that actually eats a year is not the Food and Drug Administration’s 30-day Investigational Device Exemption clock under 21 CFR 812.30. It is the stacked queue: Q-Sub, a significant-risk IDE package, institutional review board review, hospital contracting, and the 12–18 month feasibility-trial wait already published on our Panama first-in-human guide. Panama’s Ministerio de Salud (MINSA) reviews high-risk investigational device protocols — including Class III implants and innovative biomaterials — under a written rulebook that puts first patient in months, not years.

    I am Julio Martinez-Clark, CEO of bioaccess®. This is the Class III / US-startup cut: MINSA’s investigational review, Panama City surgical sites, cost and timeline versus a US IDE feasibility path, and the 21 CFR 812.28 acceptance criteria that decide whether the data can enter an IDE, 510(k), De Novo, PMA, or HDE file. For insurance bands and the country table, use the first-in-human guide. For published clocks, use the Panama clinical-trials hub and the CRO in Panama page.

    Two MINSA files — do not mix Class III registro with the trial

    Panama runs two device desks. Confusing them is how a startup burns a quarter.

    Investigational use sits with MINSA through the Dirección Nacional de Farmacia y Drogas, and with institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). The governing instruments are Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026, published in Gaceta Oficial No. 30510-C, implementing Titles III and IV of that law. MINSA’s hub is Regulación de Investigación para la Salud. The live explainer is Panama’s Decreto 21 of 2026 — Type II-accredited committees for clinical trials, RESEGIS registration before start, ordinary ethics review capped at 20 business days, parallel MINSA + ethics review for high-risk protocols, and 24-hour / 15-day serious-adverse-event clocks. Those are decree clocks, not a hub median.

    Commercial Class III sale is a different statute: Ley 90 of 26 December 2017, as modified by Ley 92 of 12 September 2019, regulated by Decreto Ejecutivo No. 490 of 4 October 2019. Risk class for registro sanitario follows current GHTF/IMDRF rules; the Dirección Nacional de Dispositivos Médicos is the classifying authority. The Panama MINSA market-access page already states the single Authorized Representative model. That holder role does not replace a MINSA/CNBI trial authorization, and a trial authorization is not a license to sell. Keep commercial registro off the first-in-human critical path.

    When I write “Class III first-in-human trials,” I mean significant-risk investigational implants, orthopedic hardware, and biomaterials that a US reviewer would treat as Class III / PMA-directed or as a high-risk De Novo. High-risk investigational protocols are the set Decreto 21 sends through parallel MINSA + ethics review. Panama does not skip review. What it skips is a US-style IDE as a precondition to first implant.

    MINSA’s investigational framework for biomaterials and Class III devices

    What actually goes in, already listed on the Panama hub:

    • Spanish protocol package — protocol, investigator brochure, informed consent, and insurance. Foreign-language drafts do not substitute.
    • RESEGIS — Registro y Seguimiento de Investigación para la Salud. Standard projects receive a registration receipt in three business days. The public list is open, no login. It is a general health-research registry, not devices-only. Your protocol still has to be in it before start.
    • Type II-accredited committee — clinical trials sit a CNBI-registered Type II committee, not an ad-hoc hospital chat.
    • Parallel MINSA + ethics — high-risk work, which is where Class III implants and novel biomaterials live, does not wait for one desk to finish before the other opens.
    • CNBI evaluation axes already on the FIH guide: scientific merit and design adequacy; risk-benefit and informed-consent adequacy; investigator and site infrastructure; preclinical data as a coherent safety narrative, not a GLP checklist; patient-protection measures, monitoring, and stopping rules.

    I am not inventing a PAHO/WHO Level 4 badge for MINSA or CNBI. INVIMA Level 4 stays a Colombia fact. Panama’s claim is a 2026 executive decree, a public research registry, accredited Type II committees, and a MINSA desk that will read a high-risk device protocol in Spanish.

    Preclinical expectations are already on the FIH guide and the early-feasibility GLP/GMP/sterility article. Under Decreto Ejecutivo 21 of 2026, Art. 102, preclinical studies, when necessary, must follow Good Laboratory Practice (GLP). MINSA’s research office (URIS) confirmed in October 2026 that this applies to preclinical studies performed in Panama. Preclinical studies done abroad do not need to be repeated locally; they must be included in the investigator’s brochure, follow recognized standards, and are assessed by the ethics committee. Either way, the ISO 14971 file and the investigator brochure must tell a coherent safety story. That is not a waiver of biocompatibility, sterility, or bench performance.

    Panama City sites and surgical investigators

    bioaccess® has coordinated first-in-human device studies at JCI-accredited hospitals in Panama City since the early 2010s — the public line on the hub. We do not operate a named Panamanian hospital. A city is not a site contract. Named principal investigator and named ward are a feasibility deliverable, not a sentence I will invent here.

    Landscape hospitals already named on the FIH guide, as city infrastructure: Hospital Santo Tomás, Hospital Nacional, Instituto Oncológico Nacional, and Punta Pacífica (Johns Hopkins Medicine International affiliate). The public Axoft FINESSE first-in-human cases ran at The Panama Clinic — already on our FDA acceptance guide. That is a site of record for a published program. It is not a bioaccess® facility.

    What a US orthopedic or biomaterial sponsor actually needs in that city:

    • Qualified surgical investigators who already implant in the indication. Therapeutic areas already published on the hub: spine, orthopedic, vascular, neurotechnology. Many physicians at major centers completed US residencies or fellowships. The workforce is bilingual. That is an operating fact on the hub, not a tourism line.
    • Early-feasibility n. Panama City metro is about 2 million people. Early-feasibility enrollment is typically 5–20 patients — the right size for a Class III first-in-human cohort. Rare disease or a larger n belongs in a multi-country plan (Panama plus El Salvador plus Brazil is the example already on the FIH guide).
    • Investigational import. Ethics approval letter, investigator brochure, importation permit. Customs is among the more efficient in Latin America (Canal / Colón Free Zone). bioaccess® runs that file. Do not hand investigational units to a commercial distributor “because they already import.”
    • Same clock as Miami. Panama City is a three-hour flight from Miami and sits on US Eastern Time.

    Cost and timeline versus a US IDE feasibility path

    Use numbers we have already published. Ask for a study-specific calendar.

    Panama (hub and FIH guide): ethics approval 3–5 weeks, with MINSA clearance available concurrently on the high-risk track; 6–8 week average to first patient with bioaccess® coordination; 3–5 month conservative envelope including site prep; $12,000–$22,000 per patient; a 10-patient first-in-human study typically $200,000–$300,000; clinical-trial insurance typically $5,000–$15,000 by risk class and enrollment; US dollar (Balboa pegged 1:1).

    United States (same pages): 6–12 months IDE + IRB on the hub table; 12–18 months to first patient on the FIH-guide country table. The statutory IDE review is 30 days. The year you lose is Q-Sub cycles, significant-risk packaging, IRB, and hospital contracting — the feasibility-trial queue this page names. A separate IDE is required for significant-risk early feasibility. Panama requires MINSA/CNBI, not a US-style IDE, to start an investigational implant.

    Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study. FDA’s Early Feasibility Studies program exists; that does not empty the US site queue. A novel biomaterial or Class III orthopedic implant with no predicate is still a legal event at a US hospital. Panama City surgical services treat it as a protocol they have run.

    FDA 21 CFR 812.28 — the acceptance criteria, not a slogan

    Foreign clinical data is eligible for FDA submission and review under 21 CFR 812.28 (final rule, 83 FR 7386, 21 February 2018). Eligibility is not clearance or approval. bioaccess® designs Panama studies for that conversation. We do not promise an FDA stamp.

    Section 812.28(a) says FDA will accept information from a well-designed, well-conducted investigation outside the United States to support an IDE or a device marketing application (PMA under section 515, HDE under 520(m), 510(k), or De Novo) when three conditions are met:

    1. Good clinical practice. The rule defines GCP as a standard for design, conduct, monitoring, auditing, recording, analysis, and reporting that keeps data credible and protects subjects. GCP here includes independent ethics-committee review and approval before initiation, continuing IEC review, and documented freely given informed consent. FDA has stated that conformance with ISO 14155:2020 will generally satisfy the GCP requirement of 812.28 — already on our FDA-acceptance guide. Investigations initiated on or after 21 February 2019 must conform to the 2018 foreign-data framework.
    2. Supporting information in 812.28(b). For a significant-risk device as defined in 812.3(m) — the Class III / biomaterial first-in-human case — submit the full (b) set: investigators and sites; protocol and results; a statement that the investigational device is identical to the US device or a detailed comparison; valid scientific evidence under 21 CFR 860.7 if you claim safety and effectiveness; IEC identity meeting 812.3(t); consent, monitoring, and investigator GCP training.
    3. FDA can validate the data through an onsite inspection or other appropriate means if the agency deems it necessary. A Panama file that cannot be inspected is not an 812.28 file. Electronic data capture, device accountability, and source documents that survive an English-speaking inspector are part of the design, not a later translation job.

    Section 812.28(e) is the residual clause: even when a foreign study does not fully meet paragraph (a), FDA may still accept the information if it believes the data are credible and accurate and that subject rights were adequately protected. Do not plan to live in (e). Build (a). Parallel rule already cited on the FDA-acceptance guide: 21 CFR 814.15 for foreign data in PMA applications. If the Panama protocol is meant to support a later US IDE, file a Q-Sub / Pre-Sub before you lock endpoints (written feedback in 75 calendar days). Endpoints and inclusion criteria have to be relevant to the intended US population; site standard of care has to be comparable to US practice.

    Public programs already on the FDA-acceptance guide: Axoft FINESSE (first four cases at The Panama Clinic; FDA Breakthrough Device Designation in 2022); Newrotex (ethics approval in Panama; FDA Pre-Sub for a 510(k) using LATAM data); ReGelTec HYDRAFIL (Colombia early-feasibility, then FDA IDE for a US pivotal). Those names are already public. I am not adding unpublished sponsors or devices under development.

    Where Class III teams burn the Panama calendar

    • Treating Decreto 21 as optional. High-risk protocols get parallel MINSA + ethics. Skipping RESEGIS or sitting a committee that is not Type II-accredited is not a shortcut.
    • Mixing commercial Class III registro (Ley 90 / Decreto 490) into the trial quote. Different directorate, different dossier, different importer.
    • Assuming GLP certificates are the ethics question. CNBI reads the risk-benefit narrative. Bring ISO 14971 and a complete investigator brochure.
    • Writing the informed consent in English and “translating later.” 812.28 wants documented consent the IEC actually approved. For FDA use, include the 21 CFR 50.25 elements. Spanish first.
    • Changing the device after first implant without a comparability memo. 812.28(b)(5) is unforgiving.
    • Reading this page as “leave Colombia.” We still run first-in-human work in Colombia when the device, sites, and file fit. INVIMA clocks are managed by our Colombian legal entity. Panama is a MINSA/CNBI country category. El Salvador is a lead first-in-human jurisdiction under DNM/SRS. If a protocol fits more than one, say so. We will not flip one country into the other.

    If you are a US orthopedic or biomaterial startup staring at a 12–18 month domestic feasibility queue, send bioaccess® the protocol stage, device risk class, intended US filing, whether the investigational unit is identical to the US unit, and whether you also need a later MINSA commercial file. We will tell you how the MINSA/CNBI clock would run.

    Explore Panama trial capabilities at bioaccessla.com/clinical-trials-panama or submit a study inquiry. Related: CRO in Panama, Decreto 21 of 2026, and the Panama first-in-human guide.

  • COFEPRIS Visor de Registros Sanitarios: public lookup of active Mexico device registrations

    On Thursday 20 August 2026, COFEPRIS published the Visor de Registros Sanitarios de Dispositivos Médicos — a public lookup of vigente (active) sanitary registrations for medical devices granted by the commission. The press piece is Comunicado de prensa 21/2026 (Ciudad de México, 20 de agosto de 2026). The tool itself sits at registros.cofepris.gob.mx/BRSDM.

    If your Mexico launch memo still says “ask the distributor for a copy of the registro,” rewrite it. You can now check the named titular yourself, against a government source that updates continuously.

    What the visor is — and what it is not

    COFEPRIS frames the visor as part of the Plan Nacional de Autonomía Digital. Implementation is two-stage. The public and health institutions can consult and verify active sanitary registrations granted by COFEPRIS. Only records that comply with applicable legal provisions are included. The platform is dynamic: continuous updates, not a one-shot PDF dump.

    Read that carefully. The visor is a public lookup of active device registrations. It does not issue a new Registro Sanitario. It does not replace a COFEPRIS application. It is not a clinical-trial database. Do not put “visor screenshot” on a board slide as if it were your authorization to sell.

    Trade coverage followed a few days later (Mexico Business News, 24 August 2026). Prefer the official gob.mx cite when you brief counsel or a distributor. Secondary write-ups are useful for awareness; they are not the primary instrument.

    Why the named titular matters more than the PDF

    Mexico market access for commercial devices still lives or dies on who holds the Registro Sanitario — the titular / marketing registration holder (MRH). The visor makes that name checkable in public, for records COFEPRIS has placed in the vigente set.

    That changes diligence:

    • Independent holder vs distributor-holder. If your Mexican distributor is the titular, they control the sanitary face of the product. Channel termination does not automatically move the certificate. If a neutral Mexican company holds the registro, you can change sales partners without restarting the file as a hostage negotiation.
    • Public verify before LOI. Ask for the registration number, then open the visor. Confirm the product description, the vigente status, and the named holder match the story in the LOI. Do not treat a scanned PDF from the partner’s shared drive as the only evidence.
    • Hospital and tender questions. Health institutions are an explicit audience in Comunicado 21/2026. Expect purchasing and clinical-engineering teams to use the same public check. Your sales deck should match what they will see.

    This is the same titular discipline bioaccess® uses across LATAM registration and importer-of-record work. Mexico’s visor simply makes the holder name harder to hand-wave.

    Stage 1: titulares have a two-week observation window

    Comunicado 21/2026 is explicit on stage one. Titulares of sanitary registrations may send observations, per registro, on the information shown in the visor. Use the corresponding request format and send it to digipris@cofepris.gob.mx within two weeks of the announcement.

    If you are the titular — or you control the Mexican company that is — treat that clock as operational, not optional. Wrong brand name, wrong model string, or a stale legal-entity display creates downstream tender and customs friction even when the underlying authorization is fine. Log which registros you reviewed, which observations you filed, and who owns the reply from DIGIPRIS.

    If your “Mexico partner” is the titular and they ignore stage one, that is a signal about how they will handle variations and tecnovigilancia later. Put it in the risk memo.

    Independent holder vs distributor-holder — decide before freight

    U.S. and EU teams still sign Mexico distribution first and “sort registration later.” The visor makes the cost of that sequence visible. Before you book a launch quarter, lock four roles:

    1. Who is the COFEPRIS titular. The legal face on the vigente registration the visor will show. Manufacturer’s Mexican branch, independent Mexican holder, or distributor-as-holder — pick one on purpose.
    2. Who is the commercial importer of record. Freight paperwork has to align with the authorized structure. A forwarder with a borrowed tax ID is not a sanitary plan.
    3. Who files tecnovigilancia and field actions. Adverse-event and safety reporting for registered devices is a local sanitary duty, not a U.S. mailbox that “will translate later.”
    4. Who owns variations. Model adds, software bumps, and sterile-barrier changes need a Mexican variation path once registro exists. Quiet EU updates do not auto-propagate into the visor.

    Distributor-as-titular is easy to sign and hard to unwind. Independent-holder structures cost more upfront and keep the certificate movable when the channel breaks. bioaccess® market access (two-part pricing: a one-time registration fee per country by device class, then a lower annual holder fee from year 2 (published for Mexico, Colombia, Brazil, Peru and Argentina on the rate card)) exists for teams that want an independent holder model across LATAM rather than a one-country PDF chase — Mexico’s visor is exactly why “distributor-only” plans break under diligence.

    FIH in Mexico is a different workstream

    A first-in-human or early-feasibility investigation in Mexico and a commercial Registro Sanitario are different files. Do not clear investigational units on a commercial registration number that does not cover the investigational configuration, and do not tell the hospital that “the visor shows we are registered, so ethics is optional.” Ethics and COFEPRIS clinical pathways keep their own calendars. Say it once and keep the columns separate on the Gantt: trial authorization on one side, commercial registro and titular on the other.

    Where teams burn quarters after Comunicado 21/2026

    • Treating the visor as the application desk. It verifies vigente records. It does not replace a Registro Sanitario filing.
    • Accepting a distributor PDF without a public check. Open the visor. Match number, product, holder, and status to the commercial story.
    • Leaving stage-one observations to “the local guy.” Two weeks from the 20 August 2026 announcement is a named window. Unfiled corrections become tender friction.
    • Mixing FIH kits with commercial registro language. Investigation and selling licenses are not the same sentence, even when both mention COFEPRIS.
    • Assuming every historical registration appears. COFEPRIS says only records that comply with applicable legal provisions are included, with continuous updates. Absence from the visor is a question for the titular and DIGIPRIS — not proof that a private scan is enough.

    How this beats generic “Mexico registration” posts

    Most content posts on Mexico device registration still recycle secondary summaries: agency overview, class language, and a soft CTA to “talk to our consultants.” Comunicado 21/2026 gives operators a primary government citation and a live URL. Use it.

    When you brief a board or a hospital system, cite the gob.mx article, name the visor URL, and show the titular check you ran. That is stronger than a slide that paraphrases a consulting firm’s evergreen Mexico page. Emergo-, MedEnvoy-, and Pure Global-style explainers can still be useful background. They are not a substitute for the commission’s own announcement of a public vigente lookup.

    Transparency and digitization are the framing COFEPRIS chose. Your job as sponsor is narrower: confirm the holder you think you hired is the holder the public record shows, and fund the structure that keeps that name under your control.

    One-page Mexico gate this week

    • List every SKU you intend to sell in Mexico in the next 24 months.
    • For each SKU with an existing registro claim, open the COFEPRIS visor and record: registration number, vigente status, named titular, date checked.
    • For each “yes, vigente,” name: commercial IOR, tecnovigilancia owner, variation owner — three lines, three document IDs.
    • If you are the titular (or control the titular entity), file stage-one observations to digipris@cofepris.gob.mx within the two-week window using the corresponding request format — per registro.
    • Separate the FIH/EFS column if you also plan Mexican patients. Different dossier, different importer, different accountability log.
    • Keep the official cite in the diligence pack: gob.mx / COFEPRIS Comunicado 21/2026.

    If those owners cannot point to the same intended-purpose sentence in Spanish, you are not ready to quote Mexican hospital revenue. For an independent holder model across LATAM, see bioaccess® market access — Mexico’s public visor is why “we will get the PDF from the distributor” is no longer a plan.

  • Design Freeze in Medical Devices: What It Means for Your Clinical Trial Timeline

    Design Freeze in Medical Devices: What It Means for Your Clinical Trial Timeline

    Design freeze is one of the most consequential decisions in medical device development — and it sits directly on the critical path to your first-in-human trial. Get it right and your clinical timeline stays intact. Get it wrong and you're looking at protocol amendments, re-verification cycles, and months of delay before a single patient is enrolled.

    This article explains what design freeze means, why it matters for regulatory submissions, and how the timing of that decision shapes everything downstream — including your IDE application, site activation, and the overall clock on your FIH program.

    What Design Freeze Actually Means

    Design freeze is the formal point at which a medical device's design is locked. From that point forward, no changes are made to specifications, materials, software, or manufacturing processes without going through a controlled change management procedure.

    Under FDA 21 CFR Part 820 and ISO 13485, design freeze is embedded within the broader design control process. It typically follows design verification and validation (V&V) and precedes transfer to manufacturing. The device you freeze is the device you test in humans. That's the core logic.

    One clarification worth making: design freeze is not the same as design lock or design transfer, though early-stage teams often use all three interchangeably. Design lock tends to be informal — something used during iterative development. Design freeze is the formal, documented event. Design transfer is what comes after, when the device moves into a manufacturing environment for clinical unit production.

    Why Design Freeze Is a Hard Dependency for Clinical Trials

    Your clinical trial protocol is written around a specific device. The device description in your IDE application, the Instructions for Use, the risk analysis, the labeling — all of it references a defined configuration. If the device changes after the protocol is finalized, you have a mismatch.

    That mismatch creates real downstream problems:

    • Protocol amendments require ethics committee and regulatory authority re-approval, adding weeks or months to your timeline
    • IDE supplements may be required if the change is significant enough to affect safety or effectiveness
    • Site training has to be repeated if the device interface or operating procedure changes
    • Informed consent documents may need revision if the risk profile shifts

    None of these are fatal on their own. Compounded, they can push a 12-month FIH program into 18 or 24 months. For a startup with a board deadline tied to first human data, that's not an abstract risk.

    The practical rule: design freeze should be completed before your IDE submission, not alongside it. Many early-stage teams treat IDE filing as a parallel track to final design iterations. That approach almost always produces re-work.

    Design Freeze and the IDE Application

    The Investigational Device Exemption (IDE) application under 21 CFR Part 812 requires a device description specific enough for FDA to evaluate safety. If your device is still changing, you can't write a stable device description — and FDA reviewers will identify inconsistencies between the device description, the risk analysis, and the testing reports. Questions will follow.

    A Pre-Submission meeting (Pre-Sub) with FDA — which bioaccess® builds into the FIH-12 program from day one — is the right place to confirm what level of design finality FDA expects before you file. For most non-significant risk devices, FDA will want to see that V&V testing was conducted on the configuration that will actually be used in the trial. For significant risk devices, the bar is higher.

    The Pre-Sub also gives you the opportunity to align on your clinical protocol, primary endpoints, and statistical plan before you've committed to a frozen design. That sequencing matters: your protocol should inform your design requirements, not the other way around.

    The Verification and Validation Connection

    Design freeze can't happen in isolation from V&V. Verification asks whether the device meets its design specifications. Validation asks whether those specifications meet user needs and intended uses. Both must be completed on the device as it will be manufactured for the trial.

    This is where teams consistently run into trouble. Bench testing is often conducted on prototypes that differ from the final clinical unit. If the clinical unit is manufactured differently — different materials, different tolerances, different assembly process — the V&V data may not be representative. FDA and ethics committees reviewing your submission will ask whether testing was conducted on the same configuration that will be used in patients.

    The answer needs to be yes. That means your manufacturing process for clinical units must be defined and controlled before you freeze. If you're using a contract manufacturer, their process needs to be qualified. If you're producing units in-house, your production records need to be in place.

    This is not a small lift for an early-stage team. It's one of the main reasons the window between design freeze and IDE submission is often longer than founders expect.

    Design Freeze Timing and Your Clinical Trial Timeline

    Here's a practical timeline structure showing how design freeze fits into the broader FIH sequence:

    12 to 18 months before first patient enrolled:

    • Complete design history file (DHF) through final design inputs and outputs
    • Conduct design V&V on clinical-representative units
    • Complete risk management file per ISO 14971

    9 to 12 months before first patient enrolled:

    • Achieve formal design freeze
    • Finalize device description for IDE application
    • Begin protocol development and Pre-Sub preparation

    6 to 9 months before first patient enrolled:

    • Submit IDE application (or prepare for ethics-only submission in applicable jurisdictions)
    • Begin site qualification and ethics submissions in parallel

    3 to 6 months before first patient enrolled:

    • Receive IDE approval or ethics committee approvals
    • Complete site activation and investigator training
    • Begin enrollment

    Design freeze sits near the top of this sequence. It's a precondition, not a concurrent activity.

    For sponsors running trials in Panama, El Salvador, Chile, or the Dominican Republic through the FIH-12 program, ethics and regulatory approvals in those jurisdictions are observed in 30 to 90 days. That compressed approval window is a structural feature of those regulatory systems — not a best-case scenario. But it only helps you if your device is frozen and your submission is ready to file. A 30-day approval window doesn't recover time lost to late design changes.

    What Happens When Design Freeze Is Delayed

    Late design freeze is one of the most common sources of FIH timeline slippage, and it compounds in ways that aren't obvious at the outset.

    Consider a team that delays freeze by three months to incorporate feedback from a usability study. Those three months push the IDE submission. The IDE submission pushes ethics committee filing. Ethics committee filing pushes site activation. Site activation pushes enrollment. By the time the delay works through the system, the program is six to nine months behind.

    This isn't hypothetical. It's the standard pattern when design freeze is treated as a development milestone rather than a clinical trial dependency.

    Post-freeze changes carry their own risk. If a significant change is required after freeze — a material substitution, a software update that affects safety, a dimensional change that shifts the risk profile — you need a formal design change process. That includes impact assessment, updated V&V testing, and potentially a protocol amendment and regulatory re-submission. Even minor changes typically add four to eight weeks when they touch regulatory submissions.

    How Design Freeze Interacts With Non-U.S. Regulatory Submissions

    If your FIH trial is running outside the United States, design freeze still anchors the submission. Ethics committees in Panama (MINSA/CNBI), Chile (ISP/MINSAL), and El Salvador (SRS/CNEIS) review the device description as part of their safety evaluation. They want to see the same thing FDA wants: a defined, tested device that matches the protocol.

    One practical difference in LatAm submissions is that some jurisdictions accept a device description supported by bench testing data without requiring a full IDE. The evidentiary bar for ethics approval isn't identical to the FDA bar. But the underlying requirement — that the device is defined and stable — is the same across all of them.

    Under FDA 21 CFR 812.28, data collected in foreign clinical investigations can support U.S. IDE and IND submissions when the trial is conducted under comparable ethical and scientific standards. That means the device used in a Panama or Chile FIH trial needs to be the same device described in the eventual U.S. submission. Design freeze is the mechanism that ensures that consistency.

    Practical Steps to Prepare for Design Freeze

    If you're planning a FIH trial and haven't yet frozen your design, here's what needs to be in place before you do:

    Design history file (DHF) completeness. All design inputs, outputs, reviews, verification, and validation records should be current and traceable. Gaps in the DHF will surface during FDA review and ethics committee submission.

    Risk management file. Your risk analysis per ISO 14971 should reflect the final device configuration. Post-freeze changes that affect the risk profile require the file to be updated.

    Clinical-representative units. The units used in V&V testing should be manufactured using the same process, materials, and controls as the units that will be used in the trial. Document this explicitly.

    Manufacturing controls. Whether you're using a contract manufacturer or producing in-house, your production process should be defined, controlled, and capable of producing consistent units. Clinical unit manufacturing is not prototype manufacturing.

    Labeling draft. Your Instructions for Use and device labeling should be drafted before freeze. Labeling is part of the device definition, and post-freeze labeling changes can require re-approval.

    Change control procedure. Changes happen even after freeze. Having a formal change control procedure in place before you freeze means you can handle them systematically rather than reactively.

    Design Freeze as a Clinical Readiness Gate

    The most useful reframe for early-stage teams is to treat design freeze as a clinical readiness gate, not just a development milestone. The question isn't "is the device good enough to freeze?" It's "is the device defined well enough to submit to FDA and ethics committees, train investigators, and enroll patients?"

    That framing changes how you prioritize the work leading up to freeze. It pulls clinical operations, regulatory affairs, and quality into the design process earlier, rather than treating them as downstream consumers of whatever development produces.

    For teams working toward a first-in-human trial in 12 to 24 months, that earlier integration is what keeps the timeline intact. The bioaccess® FIH-12 program is structured around exactly this kind of parallel-track coordination — nine workstreams running concurrently, with FDA Pre-Sub alignment and protocol development happening alongside design finalization rather than after it.

    FAQs

    What is design freeze in medical device development?
    Design freeze is the formal, documented point at which a medical device's design is locked. No changes are made to specifications, materials, software, or manufacturing processes without a controlled change management procedure. It follows design verification and validation and precedes clinical unit manufacturing.

    Does design freeze have to happen before an IDE submission?
    Yes, in practice. The IDE application requires a stable device description, and FDA evaluates safety based on the device as it will be used in the trial. If the device is still changing, the device description will be inconsistent with the testing data — which typically generates FDA questions and delays.

    What happens if you need to change the device after design freeze?
    Post-freeze changes require a formal design change process: impact assessment, updated V&V testing if the change affects safety or performance, and potentially a protocol amendment and regulatory re-submission. Depending on the magnitude of the change, expect weeks to months added to the clinical timeline.

    Is design freeze required for trials outside the United States?
    The formal requirement varies by jurisdiction, but the underlying logic is consistent. Ethics committees in Panama, Chile, El Salvador, and the Dominican Republic review the device description as part of their safety evaluation. The device needs to be defined and stable regardless of where the trial runs.

    How does design freeze affect the timeline for a first-in-human trial?
    Design freeze is a hard upstream dependency. Delays in freeze push IDE submission, which pushes ethics committee filing, which pushes site activation and enrollment. A three-month delay in freeze can translate to six to nine months of total timeline slippage when compounded through the sequence.

    What documents need to be in place before design freeze?
    At minimum: a complete design history file (DHF), a risk management file per ISO 14971, V&V records conducted on clinical-representative units, manufacturing controls documentation, a labeling draft, and a formal change control procedure.

    Can data from a LatAm FIH trial support a U.S. IDE submission if the device was frozen before the trial?
    Yes. Under FDA 21 CFR 812.28, data from foreign clinical investigations conducted under comparable ethical and scientific standards can support U.S. IDE submissions. The device used in the LatAm trial must be the same device described in the U.S. submission — which is exactly what design freeze ensures.

    Conclusion

    Design freeze is not a bureaucratic checkpoint. It's the moment your device becomes a clinical asset rather than a development project. Everything that follows in your FIH program — protocol development, IDE submission, ethics approvals, site activation, enrollment — depends on that device being defined, tested, and stable.

    Teams that hit their FIH milestones on schedule treat design freeze as a clinical readiness gate and build their development timeline backward from it. Teams that miss those milestones usually delayed freeze while running parallel development tracks that eventually collided.

    If you're 12 to 24 months from first human data and working through what your FIH timeline should look like, bioaccess® works with device and biopharma sponsors to structure that sequence from design freeze through a submission-ready evidence package.

  • Radiopharmaceutical Clinical Trials in Latin America: Regulatory Pathways and Site Requirements

    Radiopharmaceutical Clinical Trials in Latin America: Regulatory Pathways and Site Requirements

    Radiopharmaceutical development has moved fast. Lutetium-177 DOTATATE reshaped the neuroendocrine tumor space, Actinium-225 programs are advancing across multiple oncology indications, and Gallium-68 diagnostics have become standard of care in several markets. If you are running a radiopharmaceutical program today, the question is no longer whether to pursue early human data — it is where to pursue it without burning through runway while a U.S. or EU regulatory clock ticks down.

    Latin America has become a serious answer to that question. Ethics and regulatory approvals in Panama, El Salvador, Chile, and the Dominican Republic are observed in 30 to 90 days, compared to 6 to 12 months at equivalent stages in the U.S. or EU. For a seed-to-Series-B sponsor with 18 months of runway and a board milestone tied to first human data, that gap is the difference between making the next funding round and missing it.

    This article covers what you need to know before running a radiopharmaceutical clinical trial in Latin America: the regulatory pathways by jurisdiction, the site infrastructure requirements specific to radionuclide work, and the practical steps for building a submission-ready evidence package that holds up at FDA.

    Why Latin America Works for Radiopharmaceutical Development

    The appeal goes beyond speed. Latin American clinical populations are diagnostically naive to many novel radiolabeled compounds, which reduces confounding from prior treatment exposure. Patient enrollment rates at experienced oncology centers in the region tend to outpace U.S. sites for the same indications. The cost structure is also meaningfully different: per-patient costs in Panama run between $12,000 and $22,000 — a fraction of comparable U.S. trial costs.

    The regulatory data generated in these markets is not a workaround. Under FDA 21 CFR 812.28, foreign clinical data collected under ICH-GCP and ISO 14155 standards can be accepted in IDE and IND submissions when the evidence package is structured correctly. A first-in-human dataset completed in Panama or Chile can feed directly into your U.S. regulatory strategy without running a parallel domestic trial first.

    For radiopharmaceutical programs specifically, the combination of fast regulatory entry, experienced nuclear medicine infrastructure, and FDA-bridgeable data collection makes Latin America a practical first stop before a U.S. pivotal study.

    Regulatory Pathways by Jurisdiction

    Radiopharmaceuticals occupy a hybrid regulatory category across most Latin American markets — typically classified as either radiopharmaceutical drugs or radioactive medical devices, with the pathway depending on whether the compound is primarily diagnostic or therapeutic. Getting the classification right upfront saves months of back-and-forth with the relevant authority.

    Panama: MINSA and CNBI

    Panama's Ministry of Health (MINSA) and the National Bioethics Committee (CNBI) jointly govern clinical trial approvals. Radiopharmaceuticals fall under MINSA's pharmaceutical directorate, with CNBI providing parallel ethics review. The 30-to-90-day approval window reflects a well-established process for both drug and device sponsors.

    Nuclear medicine infrastructure is concentrated in Panama City, where several sites have cyclotrons or radiopharmacy capabilities for Ga-68 production and established protocols for Lu-177 administration. Ac-225 programs require additional radiation safety documentation, but the regulatory framework accommodates them. Panama is also the most cost-transparent market in the region for trial budgeting, which is why per-patient benchmarks are most reliably cited there.

    Chile: ISP and MINSAL

    Chile's Institute of Public Health (ISP) and Ministry of Health (MINSAL) share jurisdiction over clinical trial approvals. Chile has one of the most developed nuclear medicine networks in South America, with PET/CT infrastructure at major academic medical centers in Santiago and several regional cities.

    The ISP pathway for radiopharmaceuticals requires a dossier covering the investigational product's radiochemical characterization, dosimetry data, and radiation safety protocols. For Ga-68 diagnostics, ISP review tends to move faster because the compound class is well understood. For novel therapeutic isotopes like Ac-225, expect additional technical questions and plan for a documentation-heavy submission. Approval timelines are consistent with Panama's 30-to-90-day range, though novel radiopharmaceuticals can run toward the longer end.

    El Salvador: SRS and CNEIS

    El Salvador's Regulatory Health System (SRS) and the National Committee for Ethics in Health Research (CNEIS) manage clinical trial oversight. The market is smaller than Panama or Chile, but it has been used effectively for early feasibility studies where enrollment targets are modest. For radiopharmaceutical trials, the site network is more limited, and sponsors should confirm site-level radiation safety infrastructure before committing to El Salvador as a primary execution market for radionuclide therapeutics.

    Dominican Republic

    The Dominican Republic offers approval timelines comparable to Panama and El Salvador. For radiopharmaceutical development, it functions better as a secondary enrollment site than a primary execution market, given the current state of nuclear medicine infrastructure relative to Panama and Chile.

    Site Requirements for Radiopharmaceutical Trials

    Running a Lu-177, Ac-225, or Ga-68 trial is not the same as running a standard oncology drug or device study. The site infrastructure requirements are specific, and failing to qualify them upfront is one of the most common reasons radiopharmaceutical programs slip their timelines.

    Radiopharmacy and Isotope Handling

    Ga-68 diagnostic programs require either an on-site cyclotron or a reliable supply chain from a regional radiopharmacy. With a 68-minute half-life, the logistics of production-to-administration are tightly constrained. Sites in Panama City and Santiago have demonstrated this capability, but the specific supply arrangement for your compound needs to be confirmed before site selection is finalized.

    Lu-177 programs require a licensed radiopharmacy capable of receiving, labeling, and dispensing the therapeutic compound. The roughly 6.6-day half-life provides more logistical flexibility than Ga-68, but the radiation safety infrastructure requirements are higher — dedicated hot labs, appropriate waste disposal protocols, and staff trained in therapeutic radiopharmaceutical administration are all necessary.

    Ac-225 is the most demanding of the three. With a half-life of approximately 10 days and daughter isotopes requiring careful containment, Ac-225 programs need sites with advanced radiation safety programs, dosimetry expertise, and direct experience with alpha-emitting therapeutics. This narrows the qualified site pool in Latin America, but qualified sites do exist within bioaccess®'s 50-plus pre-qualified network, which was built specifically for this work.

    Imaging Infrastructure

    Most radiopharmaceutical trials require PET/CT or SPECT/CT imaging at defined protocol timepoints. Site qualification must confirm scanner availability, calibration standards, and image acquisition protocols that match your study's requirements. For multi-site trials, image standardization across sites is a protocol design consideration — not just an operations issue.

    Chile's academic centers offer modern PET/CT infrastructure with experience in quantitative imaging for research protocols. Panama's imaging infrastructure is concentrated at a smaller number of sites, which affects how many sites can realistically be activated for a radiopharmaceutical study.

    Radiation Safety and Regulatory Compliance

    Every site running a radiopharmaceutical trial needs a radiation safety officer, documented radiation protection protocols, and a license to handle the specific isotopes in the protocol. In Latin America, radiation safety oversight typically falls under the national nuclear energy authority in addition to the health ministry — CCHEN in Chile, and the National Secretariat of Energy in Panama.

    Site qualification should include a review of the site's current radiation safety license, the scope of isotopes covered, and prior experience with the specific compound class. This step cannot be skipped, and it should happen before ethics submission, not after.

    Building a Submission-Ready Evidence Package

    The goal of a Latin American radiopharmaceutical trial is not just to generate human data. It is to generate data your FDA regulatory team can use in an IND or IDE submission without repeating the study domestically.

    That requires three things from the start: a protocol designed to ICH-GCP and ISO 14155 standards, a data management system that produces audit-ready records, and a regulatory strategy that keeps the U.S. pathway in view throughout execution.

    Protocol Design Considerations

    Radiopharmaceutical first-in-human protocols need to address dosimetry, safety monitoring, and imaging endpoints in ways that satisfy both the local regulatory authority and FDA's expectations for foreign clinical data. Dosimetry assessments are typically required at multiple timepoints, with the protocol specifying how that data will be collected, analyzed, and reported.

    Stopping rules and dose escalation criteria need to be defined with the same rigor required for a U.S. IND submission. Local ethics committees in Panama and Chile are experienced with oncology protocols and will scrutinize these sections carefully.

    Data Management and Audit Readiness

    Electronic data capture systems used in Latin American radiopharmaceutical trials must meet FDA 21 CFR Part 11 requirements for electronic records — a non-negotiable condition for data destined for a U.S. submission. Data management plans should specify how imaging data, dosimetry calculations, adverse event records, and laboratory results will be captured, stored, and made available for FDA review.

    FDA Bridgeability

    Under 21 CFR 812.28, FDA can accept data from foreign clinical investigations conducted under conditions comparable to U.S. standards. For radiopharmaceutical programs, the evidence package needs to document the site's radiation safety infrastructure, principal investigator qualifications, GCP compliance of trial conduct, and the integrity of the data chain from collection to submission.

    Structuring for FDA bridgeability is not something you retrofit at the end of the trial. It has to be designed into the program from the protocol development stage.

    Working with a CRO That Knows the Terrain

    Radiopharmaceutical development in Latin America is not a standard clinical operations project. The combination of isotope-specific site requirements, dual-authority regulatory pathways, and FDA bridgeability standards demands a team that has run these programs before.

    bioaccess® operates dedicated radiopharmaceutical trial capability covering Lu-177, Ac-225, and Ga-68 programs across its 19-country Latin American and Caribbean footprint. The FIH-12 program covers all nine workstreams — from FDA Pre-Sub and IND/IDE pathway alignment through site activation, patient enrollment, data management, and delivery of a submission-ready evidence package — with a 12-month timeline guarantee on the program structure.

    The 50-plus pre-qualified site network includes locations with confirmed nuclear medicine and radiopharmacy infrastructure. Site qualification for radiopharmaceutical trials goes beyond standard GCP readiness to include radiation safety licensing, isotope handling capability, and imaging protocol standardization.

    Intake is capped at eight new programs per quarter — a reflection of the operational depth these programs require, not a volume model.

    Practical Steps Before You Commit to a Jurisdiction

    Before selecting a primary execution market for your radiopharmaceutical trial, work through these questions:

    Isotope logistics. What is the half-life of your compound, and what does that require from the site's radiopharmacy? Can the supply chain support your dosing schedule across the sites you plan to activate?

    Site qualification scope. Does the site hold a radiation safety license that covers your specific isotope? Has the principal investigator administered this compound class before, or would this be their first experience with it?

    Regulatory classification. How will the local authority classify your compound? Diagnostic and therapeutic radiopharmaceuticals follow different pathways in most jurisdictions, and getting the classification wrong at submission adds weeks to the review.

    FDA strategy alignment. Is your protocol designed to produce data FDA will accept under 21 CFR 812.28? Has your regulatory counsel reviewed it against FDA's expectations for foreign clinical data before you submit to the local authority?

    Timeline against runway. If approvals run toward the longer end of the 30-to-90-day observed range, does your program timeline still hold against your next funding milestone?

    These are not questions you answer once and move on. They should be revisited at each stage of program design, because the answers affect site selection, protocol design, and regulatory submission strategy simultaneously.

    FAQs

    What regulatory authorities govern radiopharmaceutical clinical trials in Latin America?
    It depends on the jurisdiction. Panama uses MINSA and CNBI. Chile uses ISP and MINSAL. El Salvador uses SRS and CNEIS. Beyond health ministry oversight, radiation safety for nuclear compounds typically falls under a separate national nuclear authority — CCHEN in Chile, the National Secretariat of Energy in Panama. Sponsors need to satisfy both sets of requirements before a trial can begin.

    Can data from a Latin American radiopharmaceutical trial be used in a U.S. IND submission?
    Yes, when the trial is conducted under ICH-GCP and ISO 14155 standards and the evidence package is structured per FDA 21 CFR 812.28. The data is not automatically accepted — it must be presented in a format that documents site qualifications, GCP compliance, data integrity, and the comparability of trial conditions to U.S. standards. Structuring for FDA bridgeability needs to happen at the protocol design stage, not after data collection is complete.

    Which Latin American markets have the strongest nuclear medicine infrastructure for radiopharmaceutical trials?
    Panama and Chile are the most developed for radiopharmaceutical trial execution. Chile has multiple academic centers with PET/CT infrastructure and experience in quantitative imaging research. Panama has established radiopharmacy capabilities for Ga-68 and Lu-177 programs in Panama City. Ac-225 programs require more selective site qualification in any market due to alpha-emitter handling requirements.

    How long does regulatory approval take for a radiopharmaceutical trial in Panama or Chile?
    Ethics and regulatory approvals in both markets are observed in 30 to 90 days. These are observed outcomes based on completed submissions, not a contractual guarantee from the health authorities. Novel radiopharmaceuticals — particularly Ac-225 programs — may prompt additional technical questions that push review toward the longer end of that range.

    What site infrastructure is required specifically for Lu-177 therapeutic trials?
    Sites need a licensed radiopharmacy capable of receiving, labeling, and dispensing Lu-177, along with dedicated hot lab space, radioactive waste disposal systems, and staff trained in therapeutic radiopharmaceutical administration. Dosimetry expertise and SPECT/CT imaging capability are also required for most Lu-177 protocols.

    What makes Ac-225 trials more complex than Lu-177 or Ga-68 programs?
    Ac-225 is an alpha emitter with daughter isotopes that require careful containment and monitoring. Radiation safety infrastructure requirements are higher than for Lu-177 or Ga-68, and fewer sites have the experience and licensing to handle it. Site qualification for an Ac-225 program needs to include a detailed review of the site's radiation protection program, dosimetry capabilities, and prior experience with alpha-emitting compounds.

    How does a CRO's role differ in a radiopharmaceutical trial compared to a standard device or drug study?
    A CRO running a radiopharmaceutical trial needs to manage isotope-specific site qualification, dual-authority regulatory submissions covering both health and radiation safety, imaging protocol standardization across sites, and dosimetry data management — on top of standard GCP-compliant trial operations. The operational complexity is higher, and the consequences of site qualification gaps are more severe because isotope logistics cannot be improvised mid-study.

    Start with the Right Infrastructure

    Radiopharmaceutical development in Latin America is achievable, and the regulatory speed advantage is real. But it requires more upfront site qualification work, more specific regulatory strategy, and more careful protocol design than a standard early feasibility study.

    If you are 12 to 24 months from needing first human data for a Lu-177, Ac-225, or Ga-68 program, the time to map the pathway is now — not after your IND is filed. Visit bioaccessla.com to get a preliminary country route and timeline estimate for your program.

    WordPress Category: Navigating Regulatory Landscapes in Latin America

  • Panama’s Clinical-Trial Docket Is a Public Excel File. The Industry Still Treats the Country as Opaque.

    I still hear the same sentence about Panama: small country, hard to see what is running, so treat it as a black box.

    That sentence is now a file-handling failure.

    On 23 April 2026, Panama published Decreto Ejecutivo No. 21 in Gaceta Oficial Digital No. 30510-C.1 The decree reglamenta Títulos III and IV of Ley 84 of 14 May 2019, the statute that already gave the country a health-research law.1,2 Artículo 2, numeral 9 of the decree names the tool: Plataforma web RESEGIS, the Ministerio de Salud platform for registro y seguimiento of health-research projects.1

    MINSA did not hide that list behind a consultant login.

    The official Guía introductoria a la Plataforma RESEGIS is blunt. “Para ver la lista pública de los protocolos de investigación registrados no es necesario tener un usuario activo en la plataforma, cualquier persona puede ver y acceder a la lista pública.” The same page tells you how to download that list as Excel. A second no-login module, “Ver estadísticas,” is open the same way.3

    The live public table sits at the no-login RESEGIS list.4 The columns are not a teaser. They include consecutivo, Estado en MINSA, Seguimiento CBI, title, principal investigator, site, corregimiento, registration date, health region, institutional ethics committee, ethics-approval date, funder, Universal Trial Number, executor, and enrollment status.4 You do not need a RESEGIS user to open that page. You need a browser.

    I pulled the public table on 28 August 2026. It had 1,890 rows. 1,808 were REGISTRADO. 72 were EVALUADO. Ten were EN EVALUACION.4 That is a general health-research docket, not a device-only register. Some rows look like platform tests. Filter before you brief a board. Do not treat a row as a bioaccess® study unless that fact is already on bioaccessla.com.

    The public file is the protocol list, not the whole platform. Investigator follow-up and CBI follow-up screens are login-gated. That is a user role. It is not a reason to call the docket secret. The list MINSA told the public to download is the list that is already public.

    The industry still writes Panama as if Ley 84 were the last word and the country were too small to track. Decreto 21 switched the registry language on. The consultants who still sell “Panama opacity” have not opened the Excel.

    What the decree actually changed for a trial, as opposed to a tourist brochure, is narrower than a destination essay and more useful.

    Artículo 19 splits committee accreditation. Tipo I is limited to minimum-risk work, or a minor increase above that floor. Tipo II covers that set plus intervention research, including clinical trials.1 A first-in-human device protocol is not a Tipo I file. If the ethics committee on the row is not accredited for trials, you do not have a trial committee. You have a paperwork problem.

    Artículo 44 is the ordinary ethics clock: a maximum of twenty business days from a complete file. That is the first-instance CBI review. Do not collapse it into the separate CNBI-as-superior-instance clock.

    Artículo 79 says a clinical trial’s details must be in a publicly available, freely consultable registry that meets WHO standards before the trial starts in Panama. Artículo 82 says the accredited committee must see the comprobante del registro before it certifies approval or exemption. The Excel is not a courtesy. It is the public face of a file the decree already made a start condition.

    Artículo 91 is the high-risk line. MINSA’s evaluation of those protocols and the ethics review se realizarán simultáneamente. The MINSA review does not stop the committee clock.1 A clinical-trial authorization and a commercial MINSA registration are still different files. The public RESEGIS list does not give you a sanitary registration, and a sanitary registration does not authorize an investigational lot.

    The 20 May 2026 bioaccess® reading already published that split.5,6 The article numbers above are the cite.

    That is the operational point. Opacity was the old excuse for skipping Panama diligence. The current failure mode is the opposite: paying someone to describe a country whose protocol list is already a public spreadsheet.

    Open the list before you write the feasibility memo. Confirm the committee type, the MINSA estado, the site, and whether a UTN exists. If the row is not there, you do not have a registered protocol. If the row is there and the estado is EN EVALUACION, you do not have a start. If the title is a test string, you do not have a study.

    I am not asking anyone to treat Panama as large. I am asking them to stop calling a no-login Excel an intelligence gap.

    Related bioaccess® pages

    References

    1. República de Panamá, Ministerio de Salud, Decreto Ejecutivo No. 21 de 23 de abril de 2026, “Que reglamenta los Títulos III y IV de la Ley 84 de 14 de mayo de 2019,” Gaceta Oficial Digital No. 30510-C (jueves 23 de abril de 2026). Official PDF: https://minsa.b-cdn.net/sites/default/files/publicacion-general/decreto_ejecutivo_no_21_de_23_de_abril_de_2026_-_reglamenta_titulos_iii_y_iv_ley_84_de_14-5-2019_investigacion_en_salud.pdf
    2. Ministerio de Salud de Panamá, Regulación de Investigación para la Salud (Ley 84 de 14 de mayo de 2019; Decreto Ejecutivo N. 21 de 23 de abril de 2026). https://www.minsa.gob.pa/informacion-salud/regulacion-de-investigacion-para-la-salud
    3. Ministerio de Salud de Panamá, Guía introductoria a la Plataforma RESEGIS. “Para ver la lista pública de los protocolos de investigación registrados no es necesario tener un usuario activo en la plataforma, cualquier persona puede ver y acceder a la lista pública.” Official PDF: https://www.minsa.gob.pa/sites/default/files/publicacion-general/guia_introductoria_a_la_plataforma_resegis_0.pdf
    4. Plataforma RESEGIS, Lista de Proyectos (no-login public table). https://resegis2.integrait.co/index.php/listprojects. Snapshot on disk 28 August 2026: 1,890 public rows.
    5. Julio G. Martinez-Clark, “Panama’s Decreto 21 of 2026: What the New Clinical Research Rules Mean for Sponsors,” bioaccess®, 20 May 2026. https://bioaccessla.com/blog/panama-decreto-21-2026-clinical-research-regulation-what-sponsors-need-to-know
    6. bioaccess®, “Clinical trials in Panama.” https://bioaccessla.com/clinical-trials-panama

  • What preclinical testing do I need to run a medical-device trial in Latin America?

    The question on almost every first-in-human and early-feasibility device call is the same: what preclinical testing do I need to run a medical-device trial in Latin America? Sponsors want a 21 CFR Part 58 list. Latin America does not publish one.

    The region answer, already on the live bioaccess® GLP / early-feasibility guide, is this: Brazil and El Salvador accept R&D-grade (non-GLP) preclinical data for early-feasibility device studies. Panama now has a GLP clause: Under Decreto Ejecutivo 21 of 2026, Art. 102, preclinical studies, when necessary, must follow Good Laboratory Practice (GLP). MINSA’s research office (URIS) confirmed in October 2026 that this applies to preclinical studies performed in Panama. Preclinical studies done abroad do not need to be repeated locally; they must be included in the investigator’s brochure, follow recognized standards, and are assessed by the ethics committee. The file that gets read is a coherent risk-benefit narrative — an ISO 14971 risk-management file plus an investigator’s brochure — not a GLP stamp. Country pages are cuts of that answer. The Panama cut is already published at how much animal / preclinical data for a Panama FIH. Do not duplicate it here.

    This page does not prescribe a required animal n, species, or duration for a named device. Device class, contact duration, and the specific ethics committee still decide.

    What “enough” means in official text

    Chile’s Agencia Nacional de Dispositivos Médicos published the official Guía de Investigación Clínica de Dispositivos Médicos en Humanos. Buenas Prácticas Clínicas (ANDIM, May 2026; linked from ANDIM’s technical-guides page). Principle 3(d) of that guide is the gate in one sentence: the clinical and non-clinical information available on the investigational product must be sufficient to support the proposed clinical investigation. The guide does not name GLP, BPL, or 21 CFR Part 58.

    For first-in-human and preliminary-feasibility stages, the same official guide puts the weight on preclinical / non-clinical testing and on risk evaluation, and it says those evaluations must be exhaustive. Traditional feasibility and pivotal work can add clinical data. The investigator’s manual (Manual del Investigador) exists to give the principal investigator enough safety and performance data from preclinical or clinical investigations to justify human exposure. Design justification is based on the preclinical data plus a clinical evaluation. Risk is estimated under ISO 14971 (Chilean NCh-ISO 14971:2022). The “informe de análisis de riesgo” is defined as the set of clinical and non-clinical data relevant to evaluating the device in humans.

    ANDIM also writes the limit we keep on this page: given the diversity of devices and risks, the guide does not claim to be a comprehensive, device-specific testing menu. That is the official “show us what convinces you it is safe” posture — not a consultancy line.

    Panama’s current clinical-research rulebook is Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C), which implements Titles III and IV of Ley 84 of 14 May 2019. Both instruments are listed on MINSA’s official Regulación de Investigación para la Salud page. The live Panama cut already records what that rulebook does not add: a required animal n, species, or duration, and a hidden GLP animal mandate. Read the Panama page for the country file. This page is the region parent.

    Brazil, Panama, El Salvador — the early-feasibility cut

    The live GLP / GMP / sterility guide is the published bioaccess® operational record for early-feasibility device studies we have run. Two countries accept R&D-grade (non-GLP) preclinical data, and Panama now has a GLP clause:

    • Brazil. For early-feasibility studies not intended for local market clearance, the published path is CEP (institutional ethics) under Law 14.874/24 and RDC 837/2023. CEP reviews scientific merit, risk-benefit, consent, and investigator fit. It does not apply a rigid GLP checklist. The same fact is restated on the live Brazil clinical-trials hub. ANVISA’s open-data directory at dados.anvisa.gov.br/dados/ publishes device-queue metrics and the registered produto-para-saúde catalog. It does not publish a device-trial registry. We do not invent one. Device clinical investigations (DICD) are petitioned; they are not an open trial list.
    • Panama. Ethics-committee-driven through the Comité Nacional de Bioética de Investigación (CNBI) and the institutional committee. Under Decreto Ejecutivo 21 of 2026, Art. 102, preclinical studies, when necessary, must follow Good Laboratory Practice (GLP). MINSA’s research office (URIS) confirmed in October 2026 that this applies to preclinical studies performed in Panama. Preclinical studies done abroad do not need to be repeated locally; they must be included in the investigator’s brochure, follow recognized standards, and are assessed by the ethics committee. The file still needs an ISO 14971 risk-management file and an investigator’s brochure. ISO 13485 certification is not required for an investigational early-feasibility device; fitness-for-use documentation is enough. Country detail, including Decreto 21, sits on the Panama preclinical page and the Panama FIH guide. RESEGIS is the public health-research list (listprojects) — mixed protocols, not devices-only.
    • El Salvador. The same live GLP guide: the early-feasibility path does not require GLP-compliant preclinical data. Ethics committees evaluate the totality of the evidence — biocompatibility, mechanical performance, safety margins — against the proposed risk-benefit and the patient population. The current agency is the Superintendencia de Regulación Sanitaria (SRS), srs.gob.sv. Dirección Nacional de Medicamentos (DNM) is the older name. SRS’s public servicios page lists a device expediente and a clinical-trial submission platform. There is no public approved-protocol list. We do not claim one.

    That published comparison also records what those three countries accept for the investigational unit itself: no ISO 13485 certificate as a hard early-feasibility gate, and verified (batch-level) sterility instead of a fully validated commercial sterilization process. Hospital infection-control review is often the real sterility gate. This page does not reopen that manufacturing argument; the GLP guide already holds it.

    Colombia — INVIMA is a national-authority file, not a test menu

    Colombia routes novel high-risk device investigations through INVIMA. The live GLP guide treats INVIMA as case-by-case and slower for truly novel devices without predicates (typical published clock 8–14 months). That is a pathway fact, not a preclinical quota.

    What INVIMA does publish is a device-study inventory, not a required animal or GLP list. The official attachments under INVIMA investigación clínica de dispositivos médicos include the approved-study PDF (2021–October 2025) and the not-approved PDF for the same window. Those tables name acta, radicado, protocol title, investigational product, sponsor, CRO, ethics committee, site, and PI. They do not name a required n, species, duration, or Part 58 stamp. INVIMA’s public /estudios consulta is a medicine-trial search. Do not treat it as a device-trial dump.

    The published “how much” example already on the FDA-acceptance FIH guide is the ReGelTec HYDRAFIL package that INVIMA and the independent ethics committee accepted: a 12-study GLP-where-applicable biocompatibility file compiled into a Biocompatibility Summary Report (ISO 10993 series, genotoxicity, chemical characterization and risk assessment). The same FIH guide says Latin American authorities do not prescribe a specific list of preclinical tests. The burden is on the sponsor to show the device is safe for first-in-human use. That published package is one accepted file. It is not a mandate for every Colombia or Latin America FIH.

    Chile — official guidance, no public device-trial list

    Use the May 2026 ANDIM guide above for the Chilean preclinical posture. ANDIM’s own home page, ispch.gob.cl/andim, still labels the studies platform “Plataforma de Estudios Próximamente.” There is no public Chilean device-trial registry to scrape. The medicine consulta at estudiosclinicos.ispch.gob.cl is not a device list. ISO 10993 appears in the official bibliography as Chilean NCh adoptions (NCh 2856/3 and NCh 2856/10) — genotoxicity / carcinogenicity / reproductive toxicity, and irritation / delayed hypersensitivity — not as a required animal n.

    Mexico and Argentina — do not invent a device-trial preclinical menu

    COFEPRIS public visors (medicines and the devices visor) are registro-sanitario search pages. They are not a first-in-human preclinical checklist and not a trial registry.

    ANMAT’s downloadable estudios de farmacología clínica workbook is medicines. It is not a device-trial dump. This page does not invent a COFEPRIS or ANMAT device-FIH animal rule from those surfaces.

    Public sponsor files already on the site

    Reuse only what is already public:

    • ReGelTec HYDRAFIL — ReGelTec chose Colombia and bioaccess® as its CRO for the HYDRAFIL first-in-human trial; its out-of-U.S. work in Colombia and Panama (75 patients) was later used toward CE Mark and an FDA IDE. Clinical-execution history. The preclinical package accepted by INVIMA is the 12-study GLP-where-applicable biocompatibility file on the FIH guide, not a large-animal quota for every device.
    • Axoft’s first-in-human brain-computer interface implantation in Panama, as already written on the Panama FIH guide: a novel device with no predicate, no prior human data, and R&D-grade preclinical testing. The ethics-committee path evaluated the risk-benefit narrative — investigator, monitoring, patient selection — rather than a GLP certification that did not yet exist for that device category.
    • Newrotex’s 15-day ethical approval in Panama for a first-in-human silk nerve guide, as already written on the FDA-acceptance FIH guide.
    • enVVeno’s early first-in-human clinical work in Latin America, as already written on the same FIH guide. The later FDA IDE is for a U.S. pivotal study; it is not a device clearance.

    What to put in the investigator’s brochure

    From the live early-feasibility guide, ethics committees in the recommended jurisdictions typically look for:

    • ISO 10993 biocompatibility that is scientifically valid — not necessarily GLP-wrapped
    • Mechanical and functional bench data
    • Sterilization verification (batch-level / verified sterility is accepted for early feasibility; include packaging-integrity and sterile-barrier evidence)
    • An ISO 14971 risk file
    • An investigator’s brochure that documents all available safety information
    • A written plan for which studies you will later repeat under GLP if the file is going to FDA

    For implants, the same guide names endotoxin testing (LAL or rFC; USP <85> / ISO 11737-1). This page still does not prescribe a required n, species, or duration.

    FDA later is a different question

    Whether a Latin America first-in-human file later supports an FDA IDE, 510(k), De Novo, PMA, or HDE is a 21 CFR § 812.28 question, not the Latin America start gate. The short answer is on does FDA accept LATAM clinical data. The long answer, including the typical testing frame (not a statute) and the ReGelTec package, is the FDA-acceptance FIH guide. ISO 14155 is the device GCP bridge. A Latin America ethics letter is not an FDA clearance prediction.

    Build the brochure and the trial master file as if an inspector will ask for them. That is how you keep the Latin America FIH usable later. It is not how Brazil, Panama, or El Salvador decide whether you may start.

    Related bioaccess® pages

    Official government sources cited

    If you are planning a Latin America first-in-human or early-feasibility device study, send bioaccess® the investigator’s brochure and the risk file. We will tell you whether the narrative is complete enough for the ethics committee and, where it applies, the national authority — or where the gaps are — without inventing an animal quota the official texts do not write.